Physician profile
Daniel L Kline
NPI 1780847145
$9,549.46
in general payments reported to CMS, 2019-2025
59 companies · $83.23 in 2025
The $83.23 reported for 2025 was less than what a typical Physical Medicine & Rehabilitation provider received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,063 · 2020: $1,281 · 2021: $2,592 · 2022: $2,089 · 2023: $1,215 · 2024: $227 · 2025: $83.23.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,525.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,525.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,047.15 | 2019-2023 | Reyvow, Emgality, Amyvid |
| Medtronic USA, INC. | $933.92 | 2019 | |
| Abbvie INC. | $821.03 | 2021-2023 | |
| Amgen INC. | $555.65 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $458.27 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $445.07 | 2019-2023 | |
| Allergan, INC. | $436.46 | 2019-2022 | |
| Lundbeck LLC | $388.66 | 2020-2023 | Vyepti |
| Teva Pharmaceuticals USA, INC. | $373.94 | 2019-2023 | Austedo, Austedo Xr |
| Upsher-Smith Laboratories LLC | $318.57 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $254.19 | 2020-2021 | |
| Spr Therapeutics, INC | $227.04 | 2024 | Sprint Pns System |
| Ucb, INC. | $225.65 | 2019-2022 | |
| Boston Scientific Corporation | $214.40 | 2019-2025 | Intracept |
| Biogen, INC. | $213.18 | 2021-2023 | Tysabri, Vumerity |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Kline listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.